ABT
Abbott Laboratories
Stock
$96.69−2.14 (−2.17%)Close Oct 1, 2026
Cash flow statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.9B | $9.6B | $8.6B | $7.3B | $9.6B | $10.5B | $7.9B | $6.1B | $6.3B | $5.6B | $3.2B | $3.0B | $3.7B | $3.3B | $9.3B | $9.0B | $8.7B | $7.3B | $7.0B | $5.2B |
| Capital expenditures | $2.1B | $2.2B | $2.2B | $2.2B | $1.8B | $1.9B | $2.2B | $1.6B | $1.4B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.8B | $1.5B | $1.0B | $1.1B | $1.3B | $1.7B |
| Free cash flow | $7.8B | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B | $5.7B | $4.5B | $4.9B | $4.4B | $2.1B | $1.9B | $2.6B | $2.2B | $7.5B | $7.5B | $7.7B | $6.2B | $5.7B | $3.5B |
| Stock-based compensation | $718M | $664M | $673M | $644M | $685M | $640M | $546M | $519M | $477M | $406M | $310M | $292M | $246M | $262M | $433M | $383M | $387M | $366M | $347M | $430M |
| Buybacks | $1.8B | $893M | $1.3B | $1.2B | $3.8B | $2.3B | $403M | $718M | $238M | $117M | $522M | $2.2B | $2.2B | $1.6B | $2.4B | $77M | $867M | $826M | $1.1B | $1.1B |
| Dividends paid | $4.3B | $4.1B | $3.8B | $3.6B | $3.3B | $3.2B | $2.6B | $2.3B | $2.0B | $1.8B | $1.5B | $1.4B | $1.3B | $882M | $3.2B | $2.9B | $2.7B | $2.4B | $2.2B | $2.0B |
| Dividends per share | $2.48 | $2.40 | $2.24 | $2.08 | $1.92 | — | — | — | — | — | — | — | — | — | — | $1.92 | $1.76 | $1.60 | — | — |
| Free cash flow margin | 16.8% | 16.7% | 15.1% | 12.6% | 17.9% | 20.1% | 16.5% | 14.1% | 16.0% | 16.2% | 10.0% | 9.1% | 12.8% | 11.1% | 39.5% | 34.9% | 22.0% | 20.1% | 19.3% | 13.6% |